Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

88 recalls · Class III, newest first

Class III · Low risk

HydrALAZINE Hydrochloride Tablets

Failed Impurities/Degradation Specifications: Out of Specification results in the repackaged product for impurities at the 12-month time point.

Terminated Impurity / degradation Amerisource Health Services LLC D-0039-2024
Class III · Low risk

Bendamustine HCl Injection

Labeling: Missing Label; customer complaint received that labels were partially or completely peeled off injection vial.

Completed Labeling / mix-up Baxter Healthcare Corporation NDC 10019-079-01 D-1103-2023
Class III · Low risk

Pluvicto 1

Labeling: Incorrect or Missing Lot and/or Exp Date: vials were labeled with the incorrect lot number and expiration date

Terminated Labeling / mix-up Advanced Accelerator Applications USA, Inc. NDC 69488-010-61 D-1085-2023
Class III · Low risk

0.9% Sodium Chloride Injection USP

Labeling: Not Elsewhere Classified - the description, warnings, storage information and instructions for use are either missing or partially printed.

Terminated Labeling / mix-up B. Braun Medical Inc. NDC 0264-5802-00 D-1083-2023
Class III · Low risk

Amlodipine Besylate Tablets

Subpotent Drug: Out-of-Specification test results observed in assay test at 21-month long term stability study.

Terminated Wrong potency / content Lupin Pharmaceuticals Inc. NDC 68180-721-03 D-0899-2023
Class III · Low risk

Lysteda (tranexamic acid)

Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Terminated Impurity / degradation Amring Pharmaceuticals Inc NDC 69918-301-30 D-0871-2023

Recalls by year